Molecular Testing in Lung Cancer
Surgical Pathology Clinics · 2024-06 · 17 (2) · 307-320
DOI: 10.1016/j.path.2023.11.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Pathology Clinics, 2024-06. Verfasst von Alain C Borczuk. Beteiligte Einrichtung: Anatomic Pathology, Northwell Health, 2200 Northern Boulevard Suite 104, Greenvale, NY 11548, USA. Electronic address: aborczuk@northwell.edu. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Adoption of molecular testing in lung cancer is increasing. Molecular testing for staging and prediction of response for targeted therapy remain the main indications, and although utilization of blood-based testing for tumor is growing, the use of the diagnostic cytology and tissue specimens is equally important. The pathologist needs to optimize reflex testing, incorporate stage-based algorithms, and understand types of tests for timely and complete assessment in the majority of cases. When tissue is limited, testing should capture the most frequent alterations to maximize the yield of what are largely mutually exclusive alterations, avoiding the need for repeat biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anatomic Pathology, Northwell Health, 2200 Northern Boulevard Suite 104, Greenvale, NY 11548, USA. Electronic address: aborczuk@northwell.edu.
Zitieren
APA
Borczuk, A. C. (2024). Molecular Testing in Lung Cancer. Surgical Pathology Clinics, 17(2), 307-320. https://doi.org/10.1016/j.path.2023.11.012
Vancouver
Borczuk AC. Molecular Testing in Lung Cancer. Surgical Pathology Clinics. 2024;17(2):307-320. doi:10.1016/j.path.2023.11.012
BibTeX
@article{Borczuk2024,
author = {Borczuk, Alain C},
title = {Molecular Testing in Lung Cancer},
journal = {Surgical Pathology Clinics},
year = {2024},
volume = {17},
number = {2},
pages = {307--320},
doi = {10.1016/j.path.2023.11.012}
}
EUVIMED